During the last session, MoonLake Immunotherapeutics (NASDAQ:MLTX)’s traded shares were 0.43 million, with the beta value of the company hitting 1.25. At the end of the trading day, the stock’s price was $45.70, reflecting an intraday loss of -2.52% or -$1.18. The 52-week high for the MLTX share is $64.98, that puts it down -42.19 from that peak though still a striking 17.83% gain since the share price plummeted to a 52-week low of $37.55. The company’s market capitalization is $2.92B, and the average intraday trading volume over the past 10 days was 0.68 million shares, and the average trade volume was 302.17K shares over the past three months.
MoonLake Immunotherapeutics (MLTX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. MLTX has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.59.
MoonLake Immunotherapeutics (NASDAQ:MLTX) trade information
MoonLake Immunotherapeutics (MLTX) registered a -2.52% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -2.52% in intraday trading to $45.70, hitting a weekly high. The stock’s 5-day price performance is 10.20%, and it has moved by -12.40% in 30 days. Based on these gigs, the overall price performance for the year is -19.09%. The short interest in MoonLake Immunotherapeutics (NASDAQ:MLTX) is 8.08 million shares and it means that shorts have 41.54 day(s) to cover.
The consensus price target of analysts on Wall Street is $76, which implies an increase of 39.87% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $62 and $100 respectively. As a result, MLTX is trading at a discount of -118.82% off the target high and -35.67% off the low.
MoonLake Immunotherapeutics (MLTX) estimates and forecasts
Statistics show that MoonLake Immunotherapeutics has underperformed its competitors in share price, compared to the industry in which it operates. MoonLake Immunotherapeutics (MLTX) shares have gone up 0.26% during the last six months, with a year-to-date growth rate less than the industry average at -146.58% against 16.50.
While earnings are projected to return -144.90% in 2025.
MLTX Dividends
MoonLake Immunotherapeutics is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
MoonLake Immunotherapeutics (NASDAQ:MLTX)’s Major holders
MoonLake Immunotherapeutics insiders own 15.22% of total outstanding shares while institutional holders control 98.15%, with the float percentage being 115.78%. BVF INC/IL is the largest shareholder of the company, while 177.0 institutions own stock in it. As of 2024-06-30, the company held over 21.75 million shares (or 34.7258% of all shares), a total value of $956.4 million in shares.
The next largest institutional holding, with 8.49 million shares, is of CORMORANT ASSET MANAGEMENT, LP’s that is approximately 13.5609% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $373.49 million.
Also, the Mutual Funds coming in first place with the largest holdings of MoonLake Immunotherapeutics (MLTX) shares are Price (T.Rowe) Health Sciences Fund and Fidelity Select Portfolios – Health Care . Data provided on Sep 30, 2024 indicates that Price (T.Rowe) Health Sciences Fund owns about 1.31 shares. This amounts to just over 2.07 percent of the company’s overall shares, with a $59.78 million market value. The same data shows that the other fund manager holds slightly less at 690.0, or about 1.09% of the stock, which is worth about $31.53 million.
